MIM
CRSP icon

Monashee Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Monashee Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38M Buy
+50,000
New +$2.64M 1.29% 27
2018
Q3 		– Hold
0
– – – 26
2017
Q1 		– Sell
-7,186
Closed -$141K – 70
2016
Q4 		$146K Buy
+7,186
New +$134K 0.07% 79

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Monashee Investment Management's CRSP Position: Q1 2026 in Review

Monashee Investment Management opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 50,000 shares worth $2.38M. The stake represents 1.29% of the portfolio and ranks #27 among its holdings. This is a return to the name: Monashee Investment Management previously reported a position in CRSP as recently as Q4 2016.

Monashee Investment Management first reported a position in CRSP in Q4 2016 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Monashee Investment Management held 50,000 shares of CRISPR Therapeutics worth $2.38M as of Q1 2026.
  • CRISPR Therapeutics was a new Monashee Investment Management position in Q1 2026.
  • CRISPR Therapeutics made up 1.29% of Monashee Investment Management's portfolio in Q1 2026, its #27 holding.
  • Monashee Investment Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.